BrainsWay Ltd. (NASDAQ:BWAY) Short Interest Down 39.9% in May

BrainsWay Ltd. (NASDAQ:BWAY) was the target of a significant drop in short interest during the month of May. As of May 31st, there was short interest totalling 29,200 shares, a drop of 39.9% from the May 15th total of 48,600 shares. Based on an average daily trading volume, of 76,700 shares, the short-interest ratio is currently 0.4 days.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Jump Financial LLC acquired a new stake in BrainsWay during the fourth quarter valued at $207,000. AIGH Capital Management LLC grew its position in BrainsWay by 6.5% during the third quarter. AIGH Capital Management LLC now owns 1,355,022 shares of the company’s stock valued at $5,474,000 after buying an additional 83,262 shares during the period. Legato Capital Management LLC acquired a new stake in BrainsWay during the fourth quarter valued at $542,000. Acadian Asset Management LLC acquired a new stake in BrainsWay during the third quarter valued at $28,000. Finally, Worth Venture Partners LLC grew its position in BrainsWay by 6.0% during the third quarter. Worth Venture Partners LLC now owns 336,643 shares of the company’s stock valued at $1,360,000 after buying an additional 19,045 shares during the period. Hedge funds and other institutional investors own 30.11% of the company’s stock.

BrainsWay Stock Performance

Shares of BrainsWay stock traded down $0.08 during trading on Friday, hitting $6.13. 16,692 shares of the company’s stock were exchanged, compared to its average volume of 78,808. The business has a 50-day simple moving average of $5.61 and a 200-day simple moving average of $5.99. BrainsWay has a 52-week low of $2.01 and a 52-week high of $7.61. The stock has a market capitalization of $102.06 million, a price-to-earnings ratio of -68.10 and a beta of 1.23.

BrainsWay (NASDAQ:BWAY) last issued its earnings results on Wednesday, May 8th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.02. BrainsWay had a negative net margin of 4.83% and a negative return on equity of 3.98%. The firm had revenue of $9.10 million during the quarter, compared to analysts’ expectations of $8.65 million. On average, equities analysts anticipate that BrainsWay will post 0.02 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of BrainsWay in a report on Wednesday, June 5th. Oppenheimer raised their price target on shares of BrainsWay from $10.00 to $11.00 and gave the stock an “outperform” rating in a report on Thursday, May 9th.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.